Nova Eye Medical Ltd logo

Nova Eye Medical Ltd (EYE)

Market Closed
ASX ASX
- Market Cap
- P/E Ratio
1.7% Div Yield
446,044 Volume
-0.04 Eps
Want to track EYE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

EYE is not paying dividends to its shareholders.
The last earnings report, released on Feb 24, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0033%, based on the last three reports.
Nova Eye Medical Ltd has completed 5 stock splits, with the recent split occurring on Feb 13, 2024.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on CXA (AUD).

Nova Eye Medical Ltd (EYE) FAQ

On which exchange is it traded?

Nova Eye Medical Ltd is listed on ASX.

What is its stock symbol?

The ticker symbol is EYE.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.7%.

What is its market cap?

As of today, no market cap data is available.

Has Nova Eye Medical Ltd ever had a stock split?

Nova Eye Medical Ltd had 5 splits and the recent split was on Feb 13, 2024.

Nova Eye Medical Ltd Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Victor Previn CEO
ASX Exchange
Q69076109 CUSIP
AU Country
301 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Nova Eye Medical Limited is a medical technology company specializing in the design, development, manufacture, marketing, and sales of surgical devices focused on the treatment of glaucoma. Operating on a global scale, including in Australia, the United States, Europe, and the Asia Pacific, the company aims to innovate in the field of ophthalmology. Initially founded as Ellex Medical Lasers Limited in 1970, it underwent a name change to Nova Eye Medical Limited in July 2020. With its headquarters in Kent Town, Australia, the company is dedicated to addressing the challenges of glaucoma, a leading cause of blindness worldwide, through advanced surgical solutions.

Products and Services

  • iTrack:

    This innovative glaucoma surgical device is designed to reduce intraocular pressure in adult patients suffering from open-angle glaucoma. The technology embodies a minimally invasive approach, offering a safer and efficient alternative to traditional glaucoma surgeries.

  • iTrack Advance:

    As an advancement in canaloplasty microcatheter technology, iTrack Advance represents the state-of-the-art in precision and effectiveness for glaucoma treatment. It further exemplifies Nova Eye Medical's commitment to delivering cutting-edge solutions in eye care.

  • Molteno3:

    This glaucoma drainage device is targeted at patients dealing with severe or complex glaucoma cases. Molteno3 is engineered to provide long-term relief by facilitating the drainage of excess intraocular fluid, thus managing the internal eye pressure effectively.

  • 2RT:

    2RT, standing for Retinal Rejuvenation Therapy, is a proprietary laser technology developed by Nova Eye Medical for the treatment of patients in the early to intermediate stages of age-related macular degeneration (AMD). This non-invasive treatment option marks a significant advancement in AMD care, potentially slowing or halting disease progression.

Contact Information

Address: 107 Rundle Street
Phone: 61 8 8362 0193